Kansas City,
20:23 PM

Chevalier Recieves RO3 Grant for Study of Eosinophilic Esophagitis

Rachel Chevalier, MD, Gastroenterology, was recently awarded a $150,000 R03 grant from the National Institutes of Health for research on eosinophilic esophagitis.

Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease affecting thousands of children each year leading to food aversion, failure to thrive, esophageal stricturing, and the need for long-term health care. Dr. Chevalier’s “Drug releasing microdiscs for esophageal drug delivery” study will investigate the properties of current empiric therapies and use that knowledge to develop a microscale polymer disc (microdiscs) designed to improve residence time of drug therapy in the esophagus. The prolonged residence time of the mucoadhesive discs will be expected to improve bioavailability, which decreases patient exposure to steroids, decreases costs and opens new possibilities for other pharmaceutical treatments with fewer side effects to be delivered in the same manner.

About Us

Children’s Mercy Kansas City is ranked as one of “America's Best Children's Hospitals” in nine specialties rated by U.S. News & World Report and has received MagnetTM recognition for excellence in nursing services five consecutive times. With 386 licensed beds and a medical staff of more than 750 pediatric subspecialists, we care for children from all 50 states and from around the world. In addition, our leadership in pediatric genomic medicine and individualized pediatric therapeutics is driving research and innovation in neonatology, nephrology, endocrinology, gastroenterology, neurology, heart, cancer and other subspecialties to transform outcomes for children. Children’s Mercy also is nationally recognized for innovation in psychosocial care and creating a family-centered environment focused on the unique needs of hospitalized children and their families. Our love for children powers everything we do, inspiring our research, innovations and our everyday care. Because love has no limits. And with it, neither do we.